NICE invites input on whether COVID-19 medicines in TAs 878, 1056 and 971 remain clinically and cost-effective for NHS use; consultation closes 24 September 2026.
Scottish Medicines Consortium · UK17 September 2026 Scottish Medicines Consortium celebrates 25 years of providing advice on medicines in Scotland The Scottish Medicines Consortium (SMC), part of Healthcare Improvement Scotland, is celebrating 25 year...
Scottish Medicines Consortium · UK1 April 2026 Robert Peel appointed new Chair of the Scottish Medicines Consortium
Scottish Medicines Consortium · UKSMC published positive reimbursement advice on eight medicines including mirvetuximab soravtansine, vutrisiran, and obinutuzumab for specified indications.
Scottish Medicines Consortium · UKSMC accepted atidarsagene autotemcel for metachromatic leukodystrophy and nusinersen for pre-symptomatic spinal muscular atrophy for routine NHS Scotland use.
Scottish Medicines Consortium · UKSMC published positive reimbursement advice on seven medicines including zilucoplan for myasthenia gravis, acarizax for allergic rhinitis, and cabozantinib for neuroendocrine tumours.
Scottish Medicines Consortium · UKSMC published positive reimbursement advice on seven medicines including semaglutide for cardiovascular risk reduction and odevixibat for progressive familial intrahepatic cholestasis.
Scottish Medicines Consortium · UKSMC published positive advice on six newly licensed medicines including fezolinetant, tebentafusp, and glofitamab for NHS Scotland use.
Scottish Medicines Consortium · UKSMC accepted three medicines for NHS Scotland use: enfortumab vedotin with pembrolizumab for advanced bladder cancer, amivantamab with lazertinib for advanced non-small cell lung cancer, durvalumab for limited-stage small cell lung cancer.
Scottish Medicines Consortium · UKSMC accepted osimertinib, pembrolizumab with chemoradiotherapy, and sotatercept for NHS Scotland reimbursement in specified indications.
Scottish Medicines Consortium · UK